Navigation Links
Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
Date:4/17/2009

SAN DIEGO, April 17 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will report first quarter 2009 financial results on Thursday, April 23, 2009, after the U.S. financial markets close.

Anadys will hold a conference call and webcast on Thursday, April 23, 2009 at 5:00 p.m. Eastern Daylight Time to discuss its first quarter 2009 financial results and highlights and to provide an update on its development programs, including a review of the ANA598 antiviral data that will be presented that day at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL). A live webcast of the call will be available online at www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 85383527. The webcast and telephone replay will be available through May 7, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral inducer of endogenous interferons that acts via the TLR7 pathway. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines in the areas of hepatitis C and oncology. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
2. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
3. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
4. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
5. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
6. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
7. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
8. Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
9. Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
10. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
11. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... 2016 , ... Next week on May 5 at 2:55 ... for tissue stem cell counting and expansion to gene-editing scientists and other attendees ... Genome Engineering in Burlington, Massachusetts. , The attention of most gene-editing scientists appears ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... cannabis testing technology at the Spring 2016 Marijuana Business Conference and Expo. Shimadzu’s ... residual solvents, heavy metals, and more. Expo attendees can stop by booth 1021 ...
(Date:4/27/2016)... and RESEARCH TRIANGLE PARK, N.C. ... UTHR ) announced today that Martine ... United Therapeutics will provide an overview and update on ... Annual Health Care Conference. The presentation ... 10:00 a.m. Eastern Time, and can be accessed via ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... for simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) in ... understanding disease and testing novel treatments in small animal subjects. Simultaneous PET/MRI imaging ...
Breaking Biology Technology:
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
(Date:3/17/2016)... 2016 ABI Research, the leader in ... biometrics market will reach more than $30 billion ... 2015. Consumer electronics, particularly smartphones, continue to boost ... to reach two billion shipments by 2021 at ... , Research Analyst at ABI Research. "Surveillance is ...
Breaking Biology News(10 mins):